Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma Business
-
By Kevin E. Noonan — The Biotechnology Industry Organization (BIO) held a media briefing on Federal policy issues today, with most of BIO's executive staff assembling at BIO headquarters in Washington, D.C. In addition to the media present on site, BIO hosted several more members of the press by teleconference. Jim Greenwood (at left),…
-
By Donald Zuhn — In the August issue of Life Science Leader Magazine, Randal Kirk, Chairman and CEO of the venture capital firm Third Security, LLC, writes that while some 600 to 800 life science companies are expected to go out of business or be absorbed by other companies within the next two years,…
-
By Kevin E. Noonan — The fastest-growing part of the biotech/pharma industry is anticancer drugs, according to an article in The New York Times today ("For Profit, Industry Seeks Cancer Drugs"). Written by Andrew Pollack, one of the paper's senior business and technology writers, the article highlights the interplay between scientific interest and business…
-
By Kevin E. Noonan — BioWorld Today posted an article last week about the top 25 biotech drugs currently on the market. Written by Michael Harris, Executive Editor, the piece represents a précis of a longer report by BioWorld, entitled "Market-Leading Biotechnology Drugs 2009: Blockbuster Dynamics in an Ailing Economy." In its brief overview,…
-
By Donald Zuhn — A recent article in Signals Magazine reports that biotech and specialty pharma companies raised 41% more revenue in the first six months of 2009 ($8.3 billion) than they did in the same period in 2008 ($5.9 billion) ("Biotech Financing Gathers Steam"). Despite the overall rise in funding for the first…
-
By Donald Zuhn — Last week, the Biotechnology Industry Organization (BIO) and Thomson Reuters released the results of an investor perception study conducted earlier this year that correctly forecast a rebound for the biotech industry. A 37-page report outlining the result of the study can be obtained here. Patent Docs initially reported on this…
-
By Donald Zuhn — It has not been a great year for the biotech/pharma industry. In February, BIO President and CEO Jim Greenwood noted that almost a third of BIO's membership had less than six months of cash on hand, 45% had less than one year of cash remaining, and only 10% of the…
-
By Sherri Oslick — On Wednesday Bristol-Myers Squibb and Medarex, Inc. announced that they have entered into a definitive merger agreement by which Bristol-Myers Squibb will acquire Medarex for $2.4 billion. With Medarex holding approximately $300 million in net cash and marketable securities, the purchase prices is effectively about $2.1 billion. Under the agreement,…
-
By Christopher P. Singer — FierceBiotech published its annual "Fierce 15" list of what it considers to be among the most promising of the up-and-coming companies in the biotechnology industry. FierceBiotech, a daily biotech industry news and article provider, has been publishing the Fierce 15 since 2003. The companies below (listed alphabetically) were named…
-
By Kevin E. Noonan — As reported last week by FierceBiotech, EvaluatePharma, a market forecasting firm specializing in the life sciences sector, released its prediction on the future of the pharmaceutical industry. According to EvaluatePharma, six of the top ten selling drugs by 2014 will be biologics. Today, half of the top ten best-selling…
Patent Docs 